DelMar Pharmaceuticals Inc  

(Public, OTCBB:DMPI)   Watch this stock  
Find more results for Jeffrey Garner
+0.10 (8.33%)
Apr 17 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.18 - 1.30
52 week 0.75 - 2.48
Open 1.20
Vol / Avg. 54,325.00/91,775.00
Mkt cap 31.76M
P/E     -
Div/yield     -
EPS -0.36
Shares 24.43M
Beta     -
Inst. own 0%
Feb 6, 2014
DelMar Pharmaceuticals Inc at SeeThruEquity Winter Microcap Investor Conference

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 457.46% -302.48%
Return on average equity - -1505.18%
CDP Score - -


Suite 720 999 West Broadway
+1-604-6295989 (Phone)

Website links


DelMar Pharmaceuticals, Inc. formerly Berry Only Inc., is developing new drug candidates targeting orphan cancer indications. The Company�s product development programs VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer. The Company has opened an Investigational New Drug (IND) with the United States Food & Drug Administration (FDA) to begin Phase II human clinical trials with VAL-083 in patients suffering from glioblastoma multiforme (GBM). Glioblastoma multiforme (GBM) is the common and malignant form of brain cancer.

Officers and directors

Jeffrey Bacha President, Chief Executive Officer, Director
Age: 44
Scott Praill Chief Financial Officer
Age: 46
Dennis M. Brown PhD Chief Scientific Officer, Director
Age: 63
William J. Garner M.D. Director
R. J. Toth Jr Director
Age: 50
John K. Bell Independent Director
Age: 66